No Data
SymbolStock Name
Latest PriceChg%ChgVolumeTurnoverOpenPre CloseHighLowMarket CapFloat CapSharesShs Float5D %Chg10D %Chg20D %Chg60D % Chg120D %Chg250D %Chg% Year-to-dateDiv YieldTTMTurnover RatioP/E (TTM)P/E (Static)AmplitudeIndustry
US OptionsDetailed Quotes
CORT240719C29000
- 4.50
- +1.30+40.63%
15min DelayClose Jul 1 10:20 ET
4.50High4.50Low
4.50Open3.20Pre Close5 Volume71 Open Interest29.00Strike Price2.25KTurnover69.95%IV2.20%PremiumJul 19, 2024Expiry Date3.78Intrinsic Value100Multiplier18DDays to Expiry0.72Extrinsic Value100Contract SizeAmericanOptions Type0.8036Delta0.0540Gamma7.54Leverage Ratio-0.0420Theta0.0110Rho6.05Eff Leverage0.0203Vega
Intraday
- 5D
- Daily
News
Form 144 | Corcept Therapeutics(CORT.US) Officer Proposes to Sell 357.39K in Common Stocks
SEC FILLINGS DISCLOSED/ Jul 1, $Corcept Therapeutics(CORT.US)$ Officer Robb Gary Charles intends to sell 11,000 shares of its common stock on Jul 1, with a total market value of approximately $357.39K
Form 144 | Corcept Therapeutics(CORT.US) Officer Proposes to Sell 162.45K in Common Stocks
SEC FILLINGS DISCLOSED/ Jul 1, $Corcept Therapeutics(CORT.US)$ Officer Lyon Joseph Douglas intends to sell 5,000 shares of its common stock on Jul 1, with a total market value of approximately $162.45
Form 144 | Corcept Therapeutics(CORT.US) Officer Proposes to Sell 324.9K in Common Stocks
SEC FILLINGS DISCLOSED/ Jul 1, $Corcept Therapeutics(CORT.US)$ Officer Guyer William intends to sell 10,000 shares of its common stock on Jul 1, with a total market value of approximately $324.9K. G
Corcept Therapeutics Price Target Maintained With a $35.00/Share by Piper Sandler
Piper Sandler Reiterates Overweight on Corcept Therapeutics, Maintains $35 Price Target
Piper Sandler Maintains Corcept Therapeutics(CORT.US) With Buy Rating, Maintains Target Price $35
Piper Sandler analyst David Amsellem maintains $Corcept Therapeutics(CORT.US)$ with a buy rating, and maintains the target price at $35.According to TipRanks data, the analyst has a success rate of 41